MCLEAN, Va.--(BUSINESS WIRE)--Somatus, the nation’s leading and largest value-based kidney care company, today announced it has acquired strategic assets from Lumiata, a healthcare-specific AI platform. With this acquisition, Somatus will enhance existing capabilities by leveraging Lumiata’s proven ability to accurately predict high-cost claimants and likelihood of disease progression, further advancing the Company’s ability to reduce costs for provider and health plan partners.
“We built our RenalIQ® technology platform to help providers, health plans, and our community-based care teams reach patients most in need of personalized, whole-person care,” said Satish Cheema, Chief Product and Strategy Officer at Somatus. “With the addition of Lumiata’s predictive analytics tools, and the talent behind it, we can deliver enhanced care and improved outcomes for patients sooner.”
Somatus, leveraging Lumiata’s AI and predictive capabilities, will be able to surface opportunities to reduce costs, and enable better care by providing reliable predictions for patient outcomes while also helping to identify and eliminate healthcare disparities. Lumiata is a leading AI platform able to make predictions down to the individual member level while protecting members' privacy, a key factor in Somatus’ acquisition decision.
“Somatus’ and Lumiata’s analytic capabilities and disciplines complement one another in ways that will drive even stronger healthcare outcomes for the kidney care industry,” said Lumiata’s Acting CEO and Chief Operating Officer, Jessica McCarthy, who is joining Somatus as Senior Vice President of Growth Analytics. “We are excited to join the Somatus team and help accelerate their goal of revolutionizing kidney care and creating meaningful change for the millions of Americans living with chronic kidney disease.”
Somatus partners with nephrology and primary care groups, leading health plans, and health systems to provide integrated care for patients with, or at risk of developing, kidney disease. As the market leader in value-based kidney care, Somatus' vertically integrated clinical services and technology delay or prevent disease progression, improve quality and care coordination, and increase the use of home dialysis modalities and rates of kidney transplantation. The company is headquartered in McLean, Virginia, and founded by a team of world-class healthcare operators, successful entrepreneurs, and leading clinicians treating kidney disease. For more information, please visit www.somatus.com.